Elacestrant clinical trials
Also written RAD1901, ORSERDU and ER-306323.
ClinicalTrials.gov finds 41 studies for elacestrant. How that becomes 30 here
Every study that search finds has been read, to see whether and how it gives elacestrant. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count
- 41Found by its intervention search · See all 41 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 40 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 42Give elacestrant to participants
- −2Observe patients on it, or give it outside a trial
- −10Give it beside what is tested
- 30Test it: the count on this site
Get an email when these change. Save the elacestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Jan 2023 · ORSERDU · NDA 217639 (FDA, Drugs@FDA)
- European Union
- 15 Sept 2023 · Orserdu · EMEA/H/C/005898 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
30 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 18
Stemline Therapeutics, Inc. (9) · SOLTI Breast Cancer Research Group (2) · Radius Pharmaceuticals, Inc. (2) · Kristina A. Fanucci (2) · Jules Bordet Institute (1) · Jonsson Comprehensive Cancer Center (1) · Azienda Ospedaliero-Universitaria Careggi (1) · QuantumLeap Healthcare Collaborative (1)
Often tested with
Tested in the same studies.
Abemaciclib (2) · Letrozole (1) · Tamoxifen (1) · Everolimus (1) · Anastrozole (1) · Testosterone (1) · Endoxifen (1) · Palbociclib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 4 most studied
New when their studies opened, with elacestrant beside them; studies of each.
- 2Onapristone
- 1Samuraciclib
- 1KAT6 Inhibitor MEN2312
- 1RAD140
Reaching primary completion within a year · 8
Studies that test elacestrant.
- Nov 2026ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyPhase 2 · Stemline Therapeutics, Inc.
- Dec 2026Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerPhase 1/2 · Stemline Therapeutics, Inc.
- Dec 2026Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerPhase 2 · SOLTI Breast Cancer Research Group
- Dec 2026Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerPhase 1/2 · Stemline Therapeutics, Inc.
- Jan 2027A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerPhase 2 · Gustave Roussy, Cancer Campus, Grand Paris
- Mar 2027Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR RadiotherapyPhase 2 · Azienda Ospedaliero-Universitaria Careggi
- Jul 2027Ph 2 Elacestrant in ER Positive Uterine SarcomasPhase 2 · Dana-Farber Cancer Institute
- Sep 2027Circulating Tumor DNAPhase 2 · Yale University
Studies
Open first, then newest update. How each study uses elacestrant has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 30
- A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingPhase 2Stemline Therapeutics, Inc.NCT07766018Bridging study in Japanese patientsWritten as ElacestrantReport a problem
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953In one arm for DCIS under active surveillance (RECAST)Written as ElacestrantReport a problem
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingPhase 1/2Stemline Therapeutics, Inc.NCT05386108With abemaciclib in brain metastases (ELECTRA)Written as ElacestrantReport a problem
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT05512364Against standard endocrine therapy on ctDNA relapse (TREAT ctDNA)Written as ElacestrantReport a problem
- Circulating Tumor DNARecruitingPhase 2Yale UniversityNCT06923527Adjuvant use with ctDNA monitoringWritten as ElacestrantReport a problem
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498Alone against added to a CDK4/6 inhibitorWritten as elacestrant, palbociclib, abemaciclib, ribociclibReport a problem
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)RecruitingPhase 2Kristina A. FanucciNCT07222215Added to capecitabine (CAPELA)Written as ElacestrantReport a problem
- Medical Imaging to Re-evaluate Elacestrant Clinical UsageNot yet recruitingPhase 2Jules Bordet InstituteNCT07753954Its use re-evaluated by imagingWritten as ElacestrantReport a problem
- Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCRecruitingPhase 3Women's Cancer Study Group GmbHNCT07242352Adjuvant against standard endocrine therapyWritten as ElacestrantReport a problem
- A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07209449Alone or with abemaciclib in endometrial cancerWritten as ElacestrantReport a problem
- ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerRecruitingPhase 1/2Kristina A. FanucciNCT07198724With T-DXd after CDK4/6 and endocrine therapy (ERADICATE)Written as ElacestrantReport a problem
- Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07634601With everolimus in endometrial cancerWritten as ElacestrantReport a problem
- Elacestrant in Advanced Triple Positive Breast CancerRecruitingPhase 1/2NYU Langone HealthNCT07612215With trastuzumab and pertuzumab in triple-positive breast cancerWritten as ElacestrantReport a problem
- Ph 2 Elacestrant in ER Positive Uterine SarcomasRecruitingPhase 2Dana-Farber Cancer InstituteNCT07467772Alone in ER-positive uterine sarcomaWritten as ElacestrantReport a problem
- Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingPhase 2European Institute of OncologyNCT07395336With exemestane for FES-avid lesions (COMBINE)Written as elacestrant and exemestaneReport a problem
- Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerRecruitingPhase 2SOLTI Breast Cancer Research GroupNCT05982093With or without triptorelin before surgery (PREMIERE)Written as ElacestrantReport a problem
- Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT06201234Added to olaparibWritten as Olaparib + ElacestrantReport a problem
- A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerRecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07159451Alone against with ovarian suppression before surgeryWritten as ElacestrantReport a problem
- Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR RadiotherapyNot yet recruitingPhase 2Azienda Ospedaliero-Universitaria CareggiNCT07005882With PULSAR radiotherapy before surgeryWritten as ElacestrantReport a problem
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceActive, not recruitingPhase 3Stemline Therapeutics, Inc.NCT06492616Adjuvant against standard endocrine therapy (ELEGANT)Written as ElacestrantReport a problem
See all 30 studies that test elacestrant →
Behind its US label · 1 — the studies the FDA label of ORSERDU describes
From the Clinical Studies section of ORSERDU (2026-06), as openFDA has it. A study the site does not hold is left out.
Tested on its own · 15 — no other medicine in its arm
- A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingPhase 2Stemline Therapeutics, Inc.NCT07766018Bridging study in Japanese patientsWritten as ElacestrantReport a problem
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT05512364Against standard endocrine therapy on ctDNA relapse (TREAT ctDNA)Written as ElacestrantReport a problem
- Circulating Tumor DNARecruitingPhase 2Yale UniversityNCT06923527Adjuvant use with ctDNA monitoringWritten as ElacestrantReport a problem
- Medical Imaging to Re-evaluate Elacestrant Clinical UsageNot yet recruitingPhase 2Jules Bordet InstituteNCT07753954Its use re-evaluated by imagingWritten as ElacestrantReport a problem
- Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCRecruitingPhase 3Women's Cancer Study Group GmbHNCT07242352Adjuvant against standard endocrine therapyWritten as ElacestrantReport a problem
- Ph 2 Elacestrant in ER Positive Uterine SarcomasRecruitingPhase 2Dana-Farber Cancer InstituteNCT07467772Alone in ER-positive uterine sarcomaWritten as ElacestrantReport a problem
- Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR RadiotherapyNot yet recruitingPhase 2Azienda Ospedaliero-Universitaria CareggiNCT07005882With PULSAR radiotherapy before surgeryWritten as ElacestrantReport a problem
- ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyActive, not recruitingPhase 2Stemline Therapeutics, Inc.NCT05596409Alone in CDK4/6 inhibitor-naive disease (ELCIN)Written as ElacestrantReport a problem
- Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerCompletedPhase 3Stemline Therapeutics, Inc.NCT03778931On the US labelAgainst standard endocrine therapy (EMERALD)Written as ElacestrantReport a problem
- A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic FunctionCompletedPhase 1Stemline Therapeutics, Inc.NCT06126575Single dose in severe liver impairmentWritten as Elacestrant dihydrochlorideReport a problem
- Elacestrant in Preoperative Setting, a Window of Opportunity StudyCompletedEarly Phase 1SOLTI Breast Cancer Research GroupNCT04797728Short course before surgery (ELIPSE)Written as ElacestrantReport a problem
- Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerCompletedPhase 1Stemline Therapeutics, Inc.NCT02650817Effect on oestrogen receptor imagingWritten as RAD1901Report a problem
- A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerCompletedPhase 1Stemline Therapeutics, Inc.NCT02338349First-in-human dose finding in breast cancerWritten as ElacestrantReport a problem
- Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor SymptomsTerminatedPhase 2Radius Pharmaceuticals, Inc.NCT02653417Hot flashes against placebo, as RAD1901Written as RAD1901Report a problem
- A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal WomenCompletedPhase 2Radius Pharmaceuticals, Inc.NCT00875420Hot flashes in postmenopausal women, as RAD1901Written as RAD1901Report a problem
Tested with established drugs · 7 — they are given beside it
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingPhase 1/2Stemline Therapeutics, Inc.NCT05386108With abemaciclib in brain metastases (ELECTRA)Written as ElacestrantReport a problem
- Elacestrant in Advanced Triple Positive Breast CancerRecruitingPhase 1/2NYU Langone HealthNCT07612215With trastuzumab and pertuzumab in triple-positive breast cancerWritten as ElacestrantReport a problem
- Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerRecruitingPhase 2SOLTI Breast Cancer Research GroupNCT05982093With or without triptorelin before surgery (PREMIERE)Written as ElacestrantReport a problem
- Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT06201234Added to olaparibWritten as Olaparib + ElacestrantReport a problem
- A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerRecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07159451Alone against with ovarian suppression before surgeryWritten as ElacestrantReport a problem
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingPhase 1/2Stemline Therapeutics, Inc.NCT05563220With targeted drugs in an umbrella study (ELEVATE)Written as ElacestrantReport a problem
- Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerTerminatedPhase 1/2Criterium, Inc.NCT04791384With abemaciclib in brain metastases, before its approvalWritten as ElacestrantReport a problem
Tested in a combination · 8 — another drug in the study is under test too
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953In one arm for DCIS under active surveillance (RECAST)Written as ElacestrantReport a problem
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498Alone against added to a CDK4/6 inhibitorWritten as elacestrant, palbociclib, abemaciclib, ribociclibReport a problem
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)RecruitingPhase 2Kristina A. FanucciNCT07222215Added to capecitabine (CAPELA)Written as ElacestrantReport a problem
- A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07209449Alone or with abemaciclib in endometrial cancerWritten as ElacestrantReport a problem
- ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerRecruitingPhase 1/2Kristina A. FanucciNCT07198724With T-DXd after CDK4/6 and endocrine therapy (ERADICATE)Written as ElacestrantReport a problem
- Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07634601With everolimus in endometrial cancerWritten as ElacestrantReport a problem
- Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingPhase 2European Institute of OncologyNCT07395336With exemestane for FES-avid lesions (COMBINE)Written as elacestrant and exemestaneReport a problem
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceActive, not recruitingPhase 3Stemline Therapeutics, Inc.NCT06492616Adjuvant against standard endocrine therapy (ELEGANT)Written as ElacestrantReport a problem
Beside an established treatment under test · 1 — an approved drug, surgery or radiation is what the study tests
Tested with elacestrant: Everolimus 1
Beside a new treatment under test · 7 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with elacestrant: onapristone 2 · samuraciclib 1 · KAT6 Inhibitor MEN2312 1 · RAD140 1
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerRecruitingPhase 1Stemline Therapeutics, Inc.NCT06638307Partner of new MEN2312Written as ElacestrantReport a problem
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsRecruitingPhase 1BeOne MedicinesNCT06120283Partner of new BGB-43395 in one cohortWritten as ElacestrantReport a problem
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingPhase 1/2Ellipses PharmaNCT05573126Partner of new EP0062 in one moduleWritten as ElacestrantReport a problem
- Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast CancerActive, not recruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06691035In every armPartner of a new dendritic cell vaccineWritten as ElacestrantReport a problem
- Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerTerminatedPhase 1/2Context Therapeutics Inc.NCT05618613In every armPartner of new onapristone (ELONA)Written as ElacestrantReport a problem
- A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast CancerCompletedPhase 1/2Carrick Therapeutics LimitedNCT05963997In every armPartner of new samuraciclibWritten as Elacestrant DihydrochlorideReport a problem
- A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerWithdrawnPhase 1/2Context Therapeutics Inc.NCT06938711In every armPartner of new onapristone in a rollover studyWritten as ElacestrantReport a problem
One option of several · 2 — a test or a strategy chooses among drugs
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingPhase 1/2RayzeBio, Inc.NCT06590857One endocrine choice beside new RYZ101Report a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingPhase 2University of MiamiNCT05826964One switch option guided by blood DNAWritten as Oral SERDReport a problem
Observed · 2 — patients on it are followed, or it is given outside a trial
- Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast CancerRecruitingiOMEDICO AGNCT07563595ESR1 mutation prevalence and outcomes in practiceWritten as ElacestrantReport a problem
- Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBCRecruitingSciClone PharmaceuticalsNCT06544577Real-world safety with ESR1 mutationsWritten as ELacestrantReport a problem
Codes
What other systems call elacestrant · ClinicalTrials.gg INT000889
- MeSH (NLM) C000626176elacestrantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) FM6A2627A8ELACESTRANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27278069elacestrantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C120211ElacestrantOne source FDA
- DrugBank DB06374One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626176 | elacestrant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | FM6A2627A8 | ELACESTRANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27278069 | elacestrant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C120211 | Elacestrant | One source FDA |
| DrugBank | DB06374 | — | One source Wikidata |
Also registered as elacestrant hydrochloride (UNII 8NZT0PR8AL).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.